Retatrutide Dosage Protocol (20 mg Vial)

Straightforward 12-week and 24-week planning for a 20 mg vial at 10 mg/mL.

• Retatrutide vials (20 mg each):
  • Phase 2, 12 weeks: Minimum 3 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 10 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 3 vials (48 mg required).
  • Phase 3, 24 weeks: Minimum 9 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 36 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 32 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (6 mL required).
  • Phase 2, 24 weeks: 2 bottles by volume (20 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (6 mL required).
  • Phase 3, 24 weeks: 2 bottles by volume (18 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 60 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 56 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 20 mg

Research-labeled vial

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 2 mL of bacteriostatic water to produce 10 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 100 mcg.
• Vial size: The 20 mg label is total nominal vial content, not a weekly amount.
• Vial coverage: At the 2 mg research stage, one vial supplies 10 full weekly amounts. At the 12 mg research stage, one vial supplies 1 full weekly amount with 8 mg remaining. These are mass calculations, not vial storage or discard periods.

The 20 mg protocol keeps the clinical-trial schedules separate from vial arithmetic.

• Route and frequency: Once-weekly subcutaneous administration was used in the cited phase 2 and phase 3 trials.^[1][2][3][5]
• Studied targets: The obesity phase 2 program evaluated 1 mg, 4 mg, 8 mg, and 12 mg groups, while phase 3 programs evaluated 4 mg, 9 mg, and 12 mg targets.^[1][2][3]
• 20 mg vial concentration: 20 mg divided by 2 mL equals 10 mg/mL.
• U-100 conversion: 1 unit equals 0.01 mL or 100 mcg at this concentration.
• Evidence boundary: Trial schedules describe the investigated products and populations; they are not individualized dosing instructions.^[1][3][5][6]

Phase 2 and phase 3 used related but distinct dose-escalation designs.

• Phase 2 lower-start 12 mg arm: 2 mg, 4 mg, 8 mg, and then 12 mg in four-week stages.^[1][10]
• Phase 3 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, and then 12 mg in four-week stages.^[2][3]
• Other target groups: The programs also studied lower assigned targets rather than escalating every participant to 12 mg.^[1][2][3][5]
• Measurement: The primary chart shows weekly peptide mass, U-100 units, and mL together.
• Strength consistency: The same research amount has the same peptide mass across every Retatrutide vial size; only the concentration and required volume change.

Storage and handling must follow the documentation for the exact formulation used.

• Before preparation: Keep a lyophilized vial dry, protected from light, and at the temperature stated in its product documentation.
• After preparation: Refrigerate only as permitted by the exact formulation and diluent instructions.
• Labeling: Record the 10 mg/mL concentration, preparation date, storage conditions, and documented discard date.
• Handling: Avoid vigorous shaking and unnecessary temperature cycling because peptide stability can be formulation-dependent.^[16]

Retatrutide dosing in the cited studies was structured around assigned target groups and gradual escalation. Reading each schedule in its own trial context prevents the 20 mg vial calculation from being mistaken for a universal regimen.

• The phase 2 obesity trial randomized participants to placebo or target groups of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. Higher target groups used different starting and escalation approaches, including a lower 2 mg start for improved gastrointestinal tolerability.^[1][10]
• The phase 2 type 2 diabetes trial also evaluated several assigned Retatrutide doses and an active comparator; its population and outcomes differ from the obesity trial.^[5][12]
• The TRIUMPH phase 3 program used once-weekly subcutaneous administration with assigned targets and planned four-week escalation stages.^[2]
• TRANSCEND-T2D-1 evaluated 4 mg, 9 mg, and 12 mg target doses in adults with type 2 diabetes whose glycemic control was inadequate with diet and exercise.^[3]
• The clinical-trial registry identifies the tested protocol and population; it does not validate a separately manufactured 20 mg research vial or a self-directed schedule.^[6]

Retatrutide is an investigational single molecule designed to activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

• GIP and GLP-1 receptor activity contributes to glucose-dependent insulin signaling, appetite regulation, and nutrient-response pathways.
• Glucagon receptor activity adds a distinct energy-expenditure and hepatic-signaling component to the research profile.
• Preclinical and translational work describes the balance of activity across the three receptors and the compound's extended pharmacokinetic profile.^[4]
• Reviews of multi-receptor agonists explain why triple agonism is being investigated for obesity and metabolic disease, while emphasizing that receptor activity alone does not establish a safe dose for an individual.^[7][8]

Clinical findings must be interpreted by trial, target dose, population, follow-up period, and analysis method. The values reported in one group should not be transferred to a different schedule or vial formulation.

• In the 48-week phase 2 obesity trial, mean body-weight change was dose-related, with the largest average reduction reported in the 12 mg target group.^[1]
• The phase 2 type 2 diabetes trial reported changes in glycated hemoglobin and body weight across the evaluated Retatrutide groups.^[5]
• TRANSCEND-T2D-1 reported phase 3 glycemic and body-weight outcomes at 40 weeks in adults with type 2 diabetes.^[3]
• Cardiometabolic measurements were assessed as secondary or exploratory outcomes in the clinical program and require the same population-specific interpretation.^[1][3][5][9]
• Separate research has examined liver-fat and hepatic outcomes, but those findings do not convert a 20 mg vial into a liver-treatment protocol.^[11]

The phrase Retatrutide dosing schedule can refer to several different clinical trial protocols. There is no single approved schedule because Retatrutide is still investigational and is not yet approved as a weight loss medication.^[1][2][3][5]

• In the phase 2 obesity trial, the lower-start 12 mg group used a 2 mg starting dose. The Retatrutide dose then increased to 4 mg, 8 mg, and the assigned 12 mg dose in four-week stages.^[1][10]
• The phase 3 clinical trials use related but distinct schedules. For a 12 mg target, the protocol progresses through 2 mg once weekly, 4 mg, 6 mg, 9 mg, and 12 mg once weekly, with four weeks at each escalation step.^[2][3]
• The term maintenance dose describes the assigned target phase inside that trial. It is not a recommendation to start Retatrutide, take Retatrutide, or adjust doses of Retatrutide outside a study.
• Anyone interpreting a published starting dose or maintenance dose should confirm the population, formulation, inclusion criteria, monitoring plan, and trial endpoint. A healthcare provider can explain how clinical trial evidence differs from individualized care; this research page does not provide personalized dosing.

Retatrutide works by targeting GIP, GLP-1, and glucagon receptors. Tirzepatide targets GIP and GLP-1 receptors, while semaglutide targets the GLP-1 receptor.

• Reviews discuss semaglutide and tirzepatide alongside newer multi-receptor candidates, but results from one receptor agonist cannot be used to calculate the dose of another.^[7][8]
• Because their receptor profiles and clinical programs differ, comparisons of Retatrutide for weight loss with approved therapies require carefully matched trial populations and endpoints.
• Retatrutide is an investigational drug; a 20 mg vial calculation does not establish effectiveness of Retatrutide, safety of Retatrutide, or equivalence to an approved weight management medicine.

Published weight loss results are summaries of group-level clinical trial data. They are not predictions of individual average weight loss.

• The obesity study enrolled adults with overweight or obesity and reported change from starting body weight over 48 weeks across assigned target groups.^[1]
• The trial of Retatrutide found greater average weight reduction in higher assigned groups, while individual responses and adverse events varied.^[1]
• The phase 2 diabetes research and TRANSCEND-T2D-1 also measured body weight alongside glycemic outcomes in adults with type 2 diabetes.^[3][5]
• These effects of Retatrutide must be interpreted using the relevant starting body weight, dose arm, analysis method, and follow-up period. Significant weight reduction in a study does not prove a universal benefit, a safe Retatrutide dosage for weight loss, or a suitable weight management program for an individual.

Safety findings apply to the investigated products, monitored participants, and controlled escalation plans. They do not establish the safety of an unapproved research preparation.

• Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation were among the most frequently reported adverse events.^{[1][3][5][12]}
• In the phase 2 obesity trial, gastrointestinal events were generally mild to moderate and occurred most often during dose escalation.^[1][10]
• A 2 mg starting amount improved gastrointestinal tolerability compared with a 4 mg start in the phase 2 obesity study.^[1]
• Dose-dependent heart-rate increases were observed in phase 2 and declined after peaking during follow-up.^[1]
• Retatrutide side effects, tolerability, and treatment discontinuation are part of the same evidence picture as body weight change. Outside a trial, questions about weight management and common side effects belong with a licensed healthcare provider.

Retatrutide is not yet approved by the FDA. The broader research program includes phase 3 clinical trials, but a Retatrutide dosage search often mixes trial data, vial conversions, and informal schedules.

• Human trials support reporting the schedules that investigators actually studied; they do not support inventing a different progression for convenience.^[1][2][3][5]
• Trial design papers and registries describe assigned targets, eligibility criteria, comparators, and monitoring that are not reproduced by a vial calculation.^[2][6]
• Mechanistic and review literature can explain triple-receptor agonism but cannot independently validate a clinical dose.^[4][7][8]
• Cardiovascular and hepatic discussions remain outcome-specific and should not be converted into broad treatment claims.^[9][11]
• The 20 mg page is the Retatrutide family overview. Other strength pages focus on their own concentration, U-100 conversion, vial coverage, and supply arithmetic rather than repeating this broad evidence section.

Any subcutaneous procedure should follow the governing institutional, laboratory, or clinical protocol rather than a generalized website description.^[13][14][15]

• Use a new sterile syringe and needle for every administration and for each separate vial entry.
• Clean the vial stopper and selected site, then allow the surface to dry.
• Use the needle length, angle, skinfold method, and site-rotation plan specified by the governing procedure.
• Document the research amount, U-100 units, mL, date, and administration site consistently.
• Place used sharps immediately into an appropriate sharps container.^[13][14][15]

These answers clarify how to read the 20 mg vial chart without turning research data into individualized medical advice.

• What concentration results from adding 2 mL to a 20 mg vial? The concentration is 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL or 100 mcg.
• Does a 20 mg vial change the starting dose of Retatrutide? No. Vial strength changes concentration, volume, unit markings, and vial coverage; it does not change the assigned research amount.
• How often did clinical trials use Retatrutide? The cited phase 2 and phase 3 studies used once-weekly subcutaneous administration.^[1][2][3][5]
• Did every participant escalate to 12 mg? No. Trials included multiple assigned target groups, and participants followed the protocol for their randomized group.^[1][2][3][5]
• Why are there two charts? Phase 2 and phase 3 used different escalation designs. Keeping them separate prevents the rows from being misread as one combined schedule.

This page summarizes published human research schedules and the corresponding arithmetic for a 20 mg vial. It does not establish an approved product, a recommended dose, or individualized medical advice.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Hepatology (2024): Triple agonism and hepatic steatosis research

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.